1. Pizzorno J. Total Wellness. Prima Communications. Rocklin, California. 1996: 95-102.

2. Droge W, Pottmeyer-Gerber C, et al. Glutathione augments the activation of cytotoxic T lymphocytes in vivo. Immunobiology. 1986;172(2):151-156.

3. White AC, et al. Glutathione deficiency in human disease. J Nutr Biochem. 1994;5:218-226.

4. Burgunder JM, Lauterburg BH. Decreased production of glutathione in patients with cirrhosis. Eur J Clin Invest. 1987;17:408-414.

5. Loguercio C, Blanco FD, De Girolamo V. Ethanol consumption, amino acid and glutathione blood levels in patients with and without chronic liver disease. Alcohol Clin Exp Res. 1999;23(11):1780-1784.

6. Barbaro G, Di Lorenzo G, Soldini M. Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. Am J Gastroenterol. 1996;91(12):2569-2573.

7. Staal FJ, Roederer M, Anderson MT, et al. Glutathione deficiency and human immunodeficiency virus infection. Lancet. 1992;339:909-912.

8. Alter H, Seef L. Recovery, persistence and sequelae in hepatitis C infection: a perspective on long-term outcome. Sem Liver Disease. 2000;20(1):17-35.

9. Pessione F, Degos F, Marcellin P. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology. 1998;27(6):1717-1722.

10. Dienstag JL. Management of hepatitis C: a consensus. Gastroenterology. 1997;113(2):375.

11. McClain CJ, Price S, et al. Acetaminophen hepatotoxicity: an update. Curr Gastroenterol Rep. 1999;1(1):42-49.

12. Mori M, Hara M, Wada I. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol. 2000;151(2):131-139.

13. Urgert R, Meyboom S, Kuilman M, et al. Comparison of the effect of cafetiere and flitered coffee on serum concentrations of liver aminotransferases and lipids: six-month randomized controlled trial. BMJ. 1996;313(7069):1362-1366.

14. Urgert R, Schultz AGM, Katan et al. Effects of cafestol and kahweol from coffee grounds on serum lipids and serum liver enzymes in humans. Am J Clin Nutr. 1995;61(1):149-154.

15. Etherton GM, Kochar MS. Coffee. Facts and Controversies. Arch Fam Med. 1993;2(3):317-322.

16. Michalek JE, Ketchum NS, Alchtar FZ. Postservice mortality of US Air Force veterans occupationally exposed to herbicides in Vietnam: 15-year follow-up. Am J Epidemiol. 1998;148(8):786-792.

17. Longnecker MP, Rogan WJ, Lucier G. The human health effect of DDT and PCBs and an overview of organochlorines in public health. Annu Rev Public Health. 1997;18:211-244.

18. Redlich CA, Beckett WS, Sparer J, et al. Liver disease associated with occupational exposure to the solvent dimethylformamide. Ann Int Med. 1988;108(5):680-686.

19. Pizzorno J, Murray M. Encyclopedia of Natural Medicine. Prima Communications. Rocklin, California. 1998.

20. Sanchez A, Reeser J, Lau HS, et al. Role of sugars in human neutrophilic phagocytosis. Am J Clin Nutr. 1973;26(11):1180-1184.

21. Ringsdorf W, Cheraskin E, et al. Sucrose, neutrophil phagocytosis and resistance to disease. Dent Surv. 1976;52(12):46-48.

22. Lirussi F, Sanchez B, et al. Natural killer cells in patients with chronic hepatitis C (CHC). Gut. 1998;42 (Supp 1):A32.

23. Corrao G, Ferrari PA, Galatola G. Exploring the role of diet in modifying the effect of known disease determinants: application to risk factors of liver cirrhosis. Am J Epidemiol. 1995;142(11):1136-1146.

24. Niederau C, Strohmeyer G, Heintges T, et al. Polyunsaturated phosphatidylcholine and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group. Hepatogastroenterology. 1998;45(21):797-804.

25. Lieber CS. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Heptatol. 2000;32(1 Suppl):113-128.

26. Flora K, Hahn M, Rosen H, et al. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenter. 1998;93(2):139-143.

27. Strader D, Bacon B, Hoofnagle J, et al. Use of CAM by patients in liver disease clinics. NIH Conference on Complementary and Alternative Medicine in Chronic Liver Disease. Bethesda ,Maryland. 1999.

28. Bosisio E, Benelli C, Pirola O. Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res. 1992;25:147-154.

29. Boigk G, Stroeder L, Herbst H, et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology. 1997;26:643-649.

30. Campos R, Garrido A, Guerra A, et al. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetominophen on rat liver. Planta Med. 1989;55:417-419.

31. Bernhard MC, Junker E, Hettinger A, et al. Time course of total cysteine, glutathione, and homocysteine in plasma of patients with chronic hepatitis C treated with interferon-alpha with and without supplementation with N-acetylcysteine. J Hepatol. 1998;28(5):751-755.

32. Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres. Med Klin. 1978;73(28-29):1060-1065.

33. Feher J, Deak G, Muzes G, et al. Hepatoprotective activity of silymarin (Legalon) therapy in patients with chronic liver disease. Orv Hetil. 1989;130(51):2723-2727.

34. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol (Netherlands). 1989;9(1):105-113.

35. Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blinded, randomized and multi-center trial. J Hepatol. 1998;28:615-621.

36. Lieber CS, Leo MA, Qi C, et al. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol. 2003;37:336-339.

37. Moscarella S, Giusti A, Marra F. Therapeutic and antilipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease: preliminary results. Curr Ther Res. 1993;53:98-102.

38. Alschuler L. Milk thistle: goals and objectives. Int J Integrative Med. 1999;1:29-34.

39. Arase Y, Ikeda K, Murashima N, et al. The long-term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 1997;79(8):1494-1500.

40. Wildhirt E. Experience in Germany with glycyrrhizinic acid for the treatment of chronic viral hepatitis. In: Nishioka K, Suzuki H, Mishiro S. (Eds.). Viral Hepatitis and Liver Disease. Springer-Verlag. Tokyo, Japan. 1994:658-661.

41. Xianshi S, Huiming C, et al. Clinical and laboratory observation on the effect of glycyrrhiza in acute and chronic viral hepatitis. J Tradit Chin Med. 1984;4:127-132.

42. Susuki H, Yamamato S, Hirayama C. Cianidanol therapy for HBe-antigen-positive chronic hepatitis :a multicentre, double-blind study. Liver. 1986(1);6:35-44.

43. Salama A, Mueller-Eckhardt C. Cianidanol and its metabolites bind tightly to red cells and are responsible for the production of auto- and /or drug-dependant antibodies against these cells. Br J Haematol. 1987;66(2):263-266.

44. Iwu M. Dietary botanical supplements with antiviral and anti-inflammatory properties used in the treatment of liver disorders in traditional African medicine. Complementary and Alternative Medicine in Chronic Liver Disease Conference. National Institutes of Health. Bethesda, Maryland. 1999.

45. Ferrea G. In vitro activity of a combretum micranthim extract against herpes simplex virus types 1 and 2. Antiviral Res. 1993;21:317-25.

46. Ott M, Thygarajan SP, Gupta S. Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer I and cellular transcription factors. Eur J Clin Invest. 1997;27(11):908-915.

47. Mehrotra R, Rawat S, Kulshreshta DK, et al. In vitro studies on the effect of certain natural products against heptitis B virus. Indian J Med Res. 1990;92:133-138.

48. Forton, DM, Thomas HC, Murphy CA, Allsop, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35:433-439.

49. Viviani B, Corsini E, Binaglia M, et al. Reactive oxygen species generated by glia are responsible for neuron death induced by human immunodeficiency virus-glycoprotein 120 in vitro. Neuroscience. 2001;107(1):51-58.

50. Fahn S. The endogenous toxin theory of the etiology of Parkinson's disease and a pilot trial of high-dose antioxidants in an attempt to slow the progression of illness. Ann NY Acad Sci. 1989;570:186-196.

51. Floyd RA, et al. Neuroinflammatory diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenrative disease development. Free Rad Biol Med. 1999;26(9/10):1346-1355.

52. Curtis-Prior P, Vere D, Fray P. Therapeutic value of Ginkgo biloba in reducing symptoms of decline in mental function. J Pharm Pharmacol. 1999; 51(5):535-41.

53. Ramassamy C, Clostre F, Christen Y, Costentin J. In vivo Gingko biloba extract (EGb 761) protects against neurotoxic effects induced by MPTP: investigations into its mechanisms of action. In: Christen Y, Costentin J, Lacour M (Eds.). Effects of Gingko biloba extract (EGb 761) on the central nervous system. Elsevier. Paris, France. 1992:27-36.

54. Wettstein A. Cholinesterase inhibitors and gingko extracts: are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months duration. Phytomedicine. 2000;6(6):393-401.

55. Dwight MM, Kowdley KV, Russo JE, et al. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res. 2000;49(5):311-317.

56. Schubert H, Halama P. Depressive episode primarily unresponsive to therapy in elderly patients: efficacy of Gingko biliba extract (EGB 761) in combination with antidepressants. Geriatr Forsch. 1993;3:45-53.

57. Gaby A. Gingko biloba extract: a review. Altern Med Rev. 1996;1(4):236-242.

58. Linde K, Ramirez G, Mulrow C, et al. St. John's Wort for depression. An overview and meta-analysis of randomized clinical trials. BMJ. 1996; 313(7052):253-258.

59. Schulz V, Hansel R, Tyler VE. Rational Phytotherapy: A Physician's Guide to Herbal Medicine. 4th Ed. Springer. New York, New York. 2000:57-77.